

Mendus Q1 2025 - Decent progress

Redeye provides its comment on Mendus' Q1 2025 report. CADENCE recently enrolled its first patient, while Mendus continues to focus on becoming phase III-ready with vididencel in AML in H2 2025e, which we believe will lead to business development opportunities. We update our estimates and valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Mendus Q1 2025 - Decent progress